Development and clinical assessment of new objective adherence markers for four microbicide delivery systems used in HIV prevention studies

Clinical and Translational Medicine

Table 6 Placebo product detection in vaginal swabs of the 135 Study

Time	HEC gel		Vaginal film		Vaginal insert
Time	HEC	FTIR	Glycerin	FTIR	Sorbitol	FTIR
0	0	0	0	0	0	0
15 min	100	100	100	100	100	100
6–12 h	100	100	90	100	90	80
24 h	90	50	70	90	80	20
48 h	40	50	40	70	70	40
72 h	22	50	20	40	30	40
96 h	20	60	10	30	60	50
120 h	10	50	0	20	30	50
144 h	10	50	0	10	10	40
With semen exposure
0	10	0	0	0	0	0
15 min	100	100	100	100	90	90
8–16 h^a	100	70	70	90	90	100
24 h	50	70	40	100	60	50
48 h	20	30	30	80	40	30
72 h	30	40	20	50	30	30
96 h	20	10	0	30	10	20
120 h	20	10	0	40	0	30
144 h	0	20	0	40	0	22

Numbers represent the percent of total vaginal swabs containing detectable placebo product, n = 9–10 swabs per time point
^aSwab obtained after vaginal intercourse